ENBD REIT announces Q3 NAV as at 31 December 2024
FFO increased by 51% Y-o-Y to USD 8.4 million
Occupancy topped previous quarters record, reaching 95%, showcasing robust leasing activity across the portfolio
Total property portfolio value up 3.9% Q-o-Q to USD 394 million
Net income for the 9-months YTD period increased by 65% Y-o-Y to USD 30.3 million
Dubai, United Arab Emirates: ENBD REIT (CEIC) PLC ('ENBD REIT'), the Shari'a compliant real estate investment trust managed by Emirates NBD Asset Management Limited, announces its financial results for the third quarter ended 31 December 2024. ENBD REIT's Net Asset Value ('NAV') stood at USD 216 million or USD 0.86 per share, compared to USD 202 million for the previous quarter and USD 191 million the previous year, a respective 6.9% Quarter-on-Quarter (Q-o-Q) and 13.1% Year-on-Year (Y-o-Y) increase.
The financial performance continues to improve, driven by strategic leasing, prudent cost management and efficient operating processes. Notably, the office portfolio has shown strong momentum, benefiting from robust tenant demand. The reduction in financing cost has also supported performance this past quarter.
The ongoing efforts to enhance asset performance and optimize the portfolio have driven a significant improvement in Funds From Operations (FFO), reinforcing its ability to sustain income growth. FFO surged 51% Y-o-Y to USD 8.4 million, supporting sustainable dividend payout expectation.
Portfolio valuations increased 3.9% Q-o-Q to USD 394 million, reflecting both the strength of Dubai's real estate market and ENBD REIT's proactive management approach. Occupancy remained at a record high of 95%, supported by strong tenant demand across the portfolio. Office assets continued to lead performance, with rentals and occupancies responding robustly to market demand. Most notably, Burj Daman recorded a 27% valuation increase Y-o-Y. These results highlight the resilience of the office sector and the effectiveness of ENBD REIT's leasing strategy.
Samir Kazi, Head of Real Estate at Emirates NBD Asset Management, commented:
'Our continued strong financial and operational performance conveys our ability to navigate a dynamic market while reinforcing our core portfolio. With NAV growth and rising FFO, we have delivered a 15.7% total return for the first 3 quarters of the year. Moving forward, we are eager to continue driving even greater value for our shareholders in the quarters to come.'
Operating expenses rose by 5% Y-o-Y, largely due to increased maintenance costs driven by higher occupancy levels. Fund expenses increased by 5% Y-o-Y due to an increase in fund management fees. Finance costs have declined by 5.3% Y-o-Y.
-Ends-
For more information:
ENBD REIT (Investor Relations)
Mona Zahooruddin
ENBDREITIR@EmiratesNBD.com
Company Secretary
Kathryn Miller
cosecme@equiomgroup.com
Equiom Corporate Services
Instinctif Partners (Public Relations)
Arief Zulkifli
Arief.Zulkifli@instinctif.com
ABOUT ENBD REIT
ENBD REIT (CEIC) PLC ('ENBD REIT') is a Shari'a compliant real estate investment trust managed by Emirates NBD Asset Management Limited (the 'Fund Manager' - Regulated by the DFSA), listed on Nasdaq Dubai under ticker ENBDREIT. ENBD REIT is a closed-ended investment company that was incorporated by the Fund Manager to invest in a diversified Portfolio of Shari'a-compliant real estate assets in the UAE. ENBD REIT has an unlimited duration and was established in the DIFC by the Fund Manager on 18 July 2016 under the Companies Law with the name 'Emirates Real Estate Fund Limited' and with registration number 2209. The Fund subsequently changed its name to 'ENBD REIT (CEIC) Limited' and later ENBD REIT (CEIC) PLC in line with the new DIFC Companies Law. ENBD REIT is categorised under DFSA law and regulations as a Public Fund, a Domestic Fund, an Islamic Fund, a Property Fund and a Real Estate Investment Trust (REIT). ENBD REIT has been established with the main investment objective of generating income returns and capital appreciation from real estate assets. ENBD REIT plans to achieve its objectives through the following strategies: (i) prudent acquisitions with a focus on achieving diversification; and (ii) active asset management and enhancement. For more information, visit: www.enbdreit.com
PORTFOLIO
Office:
Al Thuraya 1 (Dubai Media City)
A G+29-story high rise commercial tower, located at a prime location in Dubai Media City with views over Barsha Heights and Palm Jumeriah.
Burj Daman (DIFC)
Two and a half floors (the fund fully owns the 10th and 14th floors and half of the 15th floor) in the commercial portion of the tower in the DIFC.
DHCC 49 (Dubai Healthcare City)
G+5-story commercial complex located in the Dubai Healthcare City free zone.
DHCC 25 (Dubai Healthcare City)
G+6-story commercial tower located in the Dubai Healthcare City free zone
The Edge Building (Dubai Internet City)
A G+6-story fully leased, prime grade A office building recently constructed and located in the Dubai Internet City free zone.
Residential:
Arabian Oryx House (Barsha Heights)
A residential tower with 128 units in the free zone Barsha Heights, Dubai. Mainly comprises units of one, two and four-bed apartments.
Binghatti Terraces (Dubai Silicon Oasis)
A residential tower with 201 residential and 5 retail units in Dubai Silicon Oasis, constructed by developers with an established track record.
Alternative:
Uninest Dubailand (Dubailand)
A 424-bed student accommodation property located close to Dubai Academic City, serving students attending university across the city. 100% leased to global student accommodation provider, GSA.
South View School (Remraam)
A 132,000 sq. ft. British curriculum primary and secondary school operated by Interstar Education.
Community centre in Dubai Silicon Oasis with over 36,820 ft² of gross leasable area, comprising 25 retail units fully let to blue-chip tenants.
HIGHLIGHTS*
*All figures are as at 31st December 2024
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Post
a day ago
- Arabian Post
Loyyal Expands Maharaja Club with Global Shopping Rewards
Air India has partnered with blockchain-based loyalty specialist Loyyal to allow Maharaja Club members to earn points on everyday purchases across key brands in the United States and the United Kingdom. The collaboration enables members to accrue Maharaja Points on shopping at major retailers such as Walmart, Victoria's Secret, New Balance, GAP, Victorinox and Alamo – marking a significant expansion of the airline's loyalty programme. Members now earn up to 99 Maharaja Points per USD 100 spent at Walmart, 310 points per GBP 100 at Victoria's Secret, 300 points at Victorinox, 45 at New Balance, 180 at GAP and 64 points at Alamo. These offerings are accessible via the Maharaja Club Partner Offers page on Air India's website, where members can select a brand and follow on-screen prompts to initiate their purchases. Shailesh Kumar Singh, Head of Loyalty at Air India, commented that the alliance with Loyyal 'makes it easier for our members to earn Maharaja Points on everyday essentials and shopping, without needing to fly frequently'. Meanwhile, Loyyal CEO Ashish Kumar Singh noted that the initiative 'significantly boosts the earning potential for Maharaja Club's members,' adding that it enriches daily experiences and complements travel benefits. ADVERTISEMENT The partnership follows a broader revamp of the Maharaja Club, which adopted a simplified tier structure, updated identity and enhanced customer features. Air India has added more than 50 non-airline partners over the last 18 months, supporting its transformation under the strategy and leveraging its Star Alliance membership. The move aligns with global loyalty trends, where airlines increasingly engage shoppers via retail partnerships. By enabling points accrual through non-travel spend, loyalty programmes become more relevant to everyday consumer behaviour, fostering engagement beyond flight activity. Consumers, meanwhile, gain tangible value even during non-travel periods. Maharaja Club's integration with Star Alliance further enhances its value proposition. As noted by Air India's own commentary, elite-tier members benefit from worldwide priority check-in, lounge access at over 1,100 locations, extra baggage allowance, and the ability to accrue and redeem points across the alliance's 25 carriers. These features remain central to the programme's repositioning. Industry analysts highlight that Loyyal's blockchain-based platform offers secure, transparent point tracking and easier integration of diverse partners. Though Air India and Loyyal have not disclosed technical details publicly, Loyyal's existing reputation in travel loyalty schemes supports confidence in seamless implementation. Under the agreement, Air India continues to broaden access to Maharaja Points across shopping categories. The move targets customers traveling abroad or residing outside India, reinforcing Air India's global outreach following its Tata Group-led transformation. In support, the programme emphasises that points can be redeemed for award flights and cabin upgrades through Air India or Star Alliance partners. The timing of the launch coincides with Air India's widened network with new interline agreements and route expansions, such as recent pacts with airlines like airBaltic, Cyprus Airways and Uzbekistan Airways, aimed at increasing global connectivity. As passengers gain more travel options, the value of earning and using loyalty points is projected to grow. As more household and lifestyle brands are added to the programme, members could diversify their point accrual even further. Air India has indicated that additional partners will be announced in due course, though specifics have not yet been released. Maharaja Club members benefit from streamlined user experience with clearly stated earning rates for each participating brand. For example, spending at Victoria's Secret yields 310 points per GBP 100, while spending at Victorinox delivers 300 points per USD 100 – figures that are prominently showcased on the shopping portal. Air India's alignment with Loyyal fits within its hospitality-driven repositioning under along with fleet modernisation, training investments, new routes, and enhanced premium services. The airline aims to appeal to international leisure and business travellers – particularly those based abroad – by offering points that can accrue through both travel and lifestyle spending. Industry commentators suggest that Loyyal's blockchain solution offers underlying benefits including transparent audit trails, fraud reduction and easy tracking of reward accrual from non-travel sources. This increases both partner and consumer confidence in the integrity of the loyalty ecosystem.
Fintech News ME
a day ago
- Fintech News ME
Switzerland's Leonteq Partners with Emirates Islamic on Shari'a-Compliant Structured Products
Leonteq, a Zurich-based fintech company, announced today the formation of a partnership with Emirates Islamic, a financial institution in the UAE, to manufacture and distribute Shari'a-compliant structured products. The collaboration builds on Leonteq's strategic move into the Gulf region. In 2022, the firm introduced a Shari'a-compliant trust certificate issuance programme through IBDAA Certificate Issuer (IBDAA), a dedicated Islamic issuance vehicle. Amanie Advisors, a recognised Shari'a advisory firm, has been engaged by Leonteq to provide guidance on the Shari'a aspects of the programme and subsequent initiatives involving IBDAA. Under this partnership, Emirates Islamic will co-develop certain trust certificates issued by IBDAA and offer these products through its distribution network. Leonteq will support the initiative by providing a full range of services, including issuance arrangements, Shari'a-compliant hedging, and lifecycle management. This collaboration marks a notable development in the Islamic structured product space, bringing together Leonteq's capabilities in investment solutions, structuring, and technology with Emirates Islamic's market presence, credit standing (rated A+ by Fitch), and reach in the UAE wealth management sector. Clients of Emirates Islamic will gain access to investment solutions that were previously limited in availability or scale. These products will be issued via IBDAA, which is among the first Islamic issuance entities able to offer a broad range of payoff structures across various asset classes, supported by automation and flexible investment thresholds. Christian Spieler, CEO of Leonteq, commented: 'We are proud to partner with Emirates Islamic, a top tier institution in the Middle East. This collaboration will allow clients of Emirates Islamic to benefit from Leonteq's longstanding expertise in white-labelling solutions and marks a milestone for Leonteq's growth ambitions in the Middle East.' Farid AlMulla, CEO of Emirates Islamic, said: 'We have always endeavoured to offer Islamic solutions that make a difference in the lives of our customers and beyond. This new partnership will enable our clients, in particular, to benefit from an even bigger product universe that further enhances their investment choices and access to global markets.' Emirates Islamic, a member of the Emirates NBD Group, was established in 2004. It offers a wide range of Shari'a-compliant retail, business, and corporate banking services through a network of 40 branches across the UAE.
Arabian Post
a day ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
